array(3) { ["company_details"]=> array(13) { ["name"]=> string(28) "Bristol-Myers Squibb Company" ["slug"]=> string(37) "81631-us-bristol-myers-squibb-company" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/7b41874f-2658-484b-890c-9b9bd5a41f13" ["description"]=> string(1400) "At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html" ["address_street"]=> string(19) "430 E 29TH St FL 14" ["address_place"]=> string(8) "New York" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1887-02-28" ["website_domain"]=> string(7) "bms.com" ["website_url"]=> string(19) "https://www.bms.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(1200) ["article_count"]=> int(2495) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(90) "Eckert & Ziegler: Important decision expected in Q1 – is the share now picking up speed?" ["snippet_en"]=> string(155) "Eckert & Ziegler is considering selling or listing its subsidiary Pentixapharm. This could secure financing for the expansion of the radioisotope business." ["url"]=> string(130) "https://www.deraktionaer.de/artikel/aktien/eckert-ziegler-wichtige-entscheidung-im-q1-erwartet-aktie-nimmt-fahrt-auf-20347025.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/36dda04d-1d07-45ea-bdf2-9b5610d92a39" ["source"]=> string(15) "deraktionaer.de" ["publication_date"]=> string(10) "2024-01-07" ["categories"]=> array(4) { [0]=> string(10) "Divestment" [1]=> string(11) "Acquisition" [2]=> string(18) "Expansion & Growth" [3]=> string(25) "Business Model Resilience" } } [1]=> array(7) { ["title_en"]=> string(40) "Bartec intends to sell the food division" ["snippet_en"]=> string(167) "Bartec intends to sell the Food and BMS (Food) division of Bartec Benke in Gotteszell to Ultrakust, a company in the medium-sized segment of the Lübeck Possehl Group." ["url"]=> string(89) "https://www.verfahrenstechnik.de/bartec-beabsichtigt-verkauf-des-geschaeftsbereichs-food/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/e585400b-7bf7-42df-be8c-8524a568c6f2" ["source"]=> string(20) "verfahrenstechnik.de" ["publication_date"]=> string(10) "2023-11-13" ["categories"]=> array(4) { [0]=> string(10) "Divestment" [1]=> string(23) "Supply Chain Management" [2]=> string(11) "Acquisition" [3]=> string(25) "Business Model Resilience" } } [2]=> array(7) { ["title_en"]=> string(87) "D L Carlson Investment Group Inc. Sells 6,146 Shares of Bristol-Myers Squibb (NYSE:BMY)" ["snippet_en"]=> string(213) "D L Carlson Investment Group Inc. lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 8.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC." ["url"]=> string(126) "http://www.defenseworld.net/2023/09/13/d-l-carlson-investment-group-inc-sells-6146-shares-of-bristol-myers-squibb-nysebmy.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1ade1e94-b761-458d-8365-6f85692e43c7" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-09-13" ["categories"]=> array(10) { [0]=> string(18) "General Investment" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Acquisition" [3]=> string(24) "Quarterly/Annual Figures" [4]=> string(13) "Credit Rating" [5]=> string(12) "Stock Market" [6]=> string(10) "Divestment" [7]=> string(31) "Financial Update/Profit Warning" [8]=> string(11) "Regulations" [9]=> string(14) "Issuing Shares" } } [3]=> array(7) { ["title_en"]=> string(78) "Bristol Myers Squibb will close one of its manufacturing plants in Puerto Rico" ["snippet_en"]=> string(99) "This closure, which will affect about 400 employees, has caused surprise and concern on the island." ["url"]=> string(121) "https://acento.com.do/economia/bristol-myers-squibb-cerrara-una-de-sus-plantas-de-manufactura-en-puerto-rico-9209991.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/02ade06f-d71c-41e1-a512-090e2bdf76d2" ["source"]=> string(13) "acento.com.do" ["publication_date"]=> string(10) "2023-06-16" ["categories"]=> array(2) { [0]=> string(10) "Divestment" [1]=> string(27) "Fear, Uncertainty and Doubt" } } [4]=> array(7) { ["title_en"]=> string(55) "Bristol Myers closes its plant in Humacao - Jay Fonseca" ["snippet_en"]=> string(256) "The pharmaceutical company Bristol-Myers Squibb closes its operations in Humacao, sources from Cuarto Poder (WAPA-TV) confirmed. The newspaper El Vocero initially reported the closure, which could cause the loss of hundreds of jobs and that responds, in..." ["url"]=> string(65) "https://jayfonseca.com/bristol-myers-cierra-su-planta-en-humacao/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/36e54fe4-d467-41a4-b3c7-4b83ac75908b" ["source"]=> string(14) "jayfonseca.com" ["publication_date"]=> string(10) "2023-06-15" ["categories"]=> array(2) { [0]=> string(10) "Divestment" [1]=> string(7) "Layoffs" } } [5]=> array(7) { ["title_en"]=> string(69) "SOURCES: Pharmaceutical Bristol Myers in Humacao will close its doors" ["snippet_en"]=> string(203) "After 50 years of operations in Puerto Rico, the Bristol-Myers Squibb plant will close its operations in Humacao, a corporate determination that could impact 400 direct jobs and hundreds more indirectly," ["url"]=> string(121) "https://www.elvocero.com/economia/otros/cierra-bristol-myers-de-humacao/article_949ed64e-0bac-11ee-b2a2-c72067fd0ef7.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/79b1a710-a9dd-4e29-abd9-13e111b3f2c4" ["source"]=> string(12) "elvocero.com" ["publication_date"]=> string(10) "2023-06-15" ["categories"]=> array(3) { [0]=> string(10) "Downsizing" [1]=> string(10) "Divestment" [2]=> string(7) "Layoffs" } } [6]=> array(7) { ["title_en"]=> string(95) "Insiders Selling Zoom Video Communications, Bristol-Myers Squibb And This Footwear Manufacturer" ["snippet_en"]=> string(283) "The Nasdaq closed lower on Thursday after the Fed increased rates by 25 basis points on Wednesday. When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Below is a look at a few recent notable insider sales." ["url"]=> string(88) "https://www.fidelity.com/news/article/international/202305050802BENZINGAFULLNGTH32236640" ["image_url"]=> NULL ["source"]=> string(12) "fidelity.com" ["publication_date"]=> string(10) "2023-05-05" ["categories"]=> array(3) { [0]=> string(10) "Divestment" [1]=> string(7) "Economy" [2]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(77) "Breakingviews - Breakingviews - Bristol Myers deal gamble pays off twice over" ["snippet_en"]=> string(302) "Bristol Myers Squibb has landed two birds in the bush. When the $134 billion U.S. drug firm agreed to buy rival oncology specialist Celgene for $74 billion in 2019, it had to divest an autoimmune drug to satisfy regulators. Instead of keeping Celgene’ s proven blockbuster Otezla, it sold the drug to" ["url"]=> string(147) "https://www.reuters.com/article/us-bristol-myers-psoriasis-breakingviews/breakingviews-bristol-myers-deal-gamble-pays-off-twice-over-idINKBN27J24Y/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/016097ca-2260-4e10-9a60-1206b9891f23" ["source"]=> string(11) "reuters.com" ["publication_date"]=> string(10) "2020-11-03" ["categories"]=> array(2) { [0]=> string(10) "Divestment" [1]=> string(11) "Acquisition" } } [8]=> array(7) { ["title_en"]=> string(61) "Breakingviews - Bristol Myers deal gamble pays off twice over" ["snippet_en"]=> string(223) "Bristol Myers Squibb has landed two birds in the bush. When the $134 billion U.S. drug firm agreed to buy rival oncology specialist Celgene for $74 billion in 2019, it had to divest an autoimmune drug to satisfy regulators." ["url"]=> string(145) "https://uk.reuters.com/article/us-bristol-myers-psoriasis-breakingviews/breakingviews-bristol-myers-deal-gamble-pays-off-twice-over-idukkbn27j24y" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6714d886-cd51-4f92-99e0-7f6f42fdbee3" ["source"]=> string(11) "reuters.com" ["publication_date"]=> string(10) "2020-11-03" ["categories"]=> array(2) { [0]=> string(10) "Divestment" [1]=> string(11) "Acquisition" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(254) } [1]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(163) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(151) } [3]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(94) } [4]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(89) } [5]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(76) } [6]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(74) } [7]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(64) } [8]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(63) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(60) } [10]=> array(2) { ["name"]=> string(6) "Merger" ["count"]=> int(60) } [11]=> array(2) { ["name"]=> string(17) "Energy Management" ["count"]=> int(56) } [12]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(54) } [13]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(47) } [14]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(47) } [15]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(45) } [16]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(45) } [17]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(42) } [18]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(39) } [19]=> array(2) { ["name"]=> string(25) "Business Model Resilience" ["count"]=> int(35) } [20]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(35) } [21]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(33) } [22]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(32) } [23]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(28) } [24]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(27) } [25]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(26) } [26]=> array(2) { ["name"]=> string(12) "Going Public" ["count"]=> int(24) } [27]=> array(2) { ["name"]=> string(10) "Divestment" ["count"]=> int(22) } [28]=> array(2) { ["name"]=> string(9) "Valuation" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(15) "Blogs & Columns" ["count"]=> int(21) } } } 81631-us-bristol-myers-squibb-company